Upadacitinib shows unique benefit early in TNF-naive perianal Crohn’s disease

Upadacitinib improved fistula outcomes in adults with perianal Crohn’s disease, with the strongest benefit reported among those who had no history of tumor necrosis factor inhibition use and those treated earlier in their disease course.Retrospective cohort study data published in Clinical Gastroenterology and Hepatology showed that 45.5% of patients achieved clinical response and 39.4%